| abstract |
The invention relates to a novel compound, N,N'-bis (3-aminopropyl) cyclohexane-1,4-diamine, having formula (I) which is prepared by hydrogenation using a Raney nickel catalyst of N,N'-bis (2-cyanoethyl)-cyclohexane-1,4-diamine, the latter being prepared by reaction between 1,4-cyclohexanediamine and acrylonitrile. The oral administration of the tetramethanesulphonate monohydrate of (I) to genetically alcoholic mice (from the UChB strain from the University of Chili) causes a significant reduction in the consumption of alcohol. The activity of said compound continues for a certain amount of time following the treatment period. Moreover, there is practically zero disulfiram-type adverse effect, which is advantageous given the disagreeable aspect of using some antialcoholic agents, such as calcium cyanamide and said disulfiram. In this way, the inventive compounds can be used to prepare medicaments for the therapeutic and/or prophylactic treatment of alcoholism in mammals, including humans. |